Single-patient (n-of-1) trials: a pragmatic clinical decision methodology for patient-centered comparative effectiveness research

Abstract

Objective To raise awareness among clinicians and epidemiologists that single-patient (n-of-1) trials are potentially useful for informing personalized treatment decisions for patients with chronic conditions. Study Design and Setting We reviewed the clinical and statistical literature on methods and applications of single-patient trials and then critically evaluated the needs for further methodological developments. Results Existing literature reports application of 2,154 single-patient trials in 108 studies for diverse clinical conditions; various recent commentaries advocate for wider application of such trials in clinical decision making. Preliminary evidence from several recent pilot acceptability studies suggests that single-patient trials have the potential for widespread acceptance by patients and clinicians as an effective modality for increasing the therapeutic precision. Bayesian and adaptive statistical methods hold promise for increasing the informational yield of single-patient trials while reducing participant burden, but are not widely used. Personalized applications of single-patient trials can be enhanced through further development and application of methodologies on adaptive trial design, stopping rules, network meta-analysis, washout methods, and methods for communicating trial findings to patients and clinicians. Conclusions Single-patient trials may be poised to emerge as an important part of the methodological armamentarium for comparative effectiveness research and patient-centered outcomes research. By permitting direct estimation of individual treatment effects, they can facilitate finely graded individualized care, enhance therapeutic precision, improve patient outcomes, and reduce costs.

The Identification of Two New ABCB11 Gene Mutations and the Treatment Outcome in a Young Adult with Benign Recurrent Intrahepatic Cholestasis: A Case Report

“…Therefore, n-of-1 trial, which focus on the objective determination of the optimal therapy for a single individual could help improve the clinical outcome of the patients. As the chronic, benign result, and recurrent episodic characters of BRIC, N-of-1 trail would be suitable for evaluating the treatments of this disease (20).…”

Clinical Trials in Neurovirology: Successes, Challenges, and Pitfalls

“…In settings, where not all parameters are known at the outset of the trial to plan an a priori, Bwell-powered^experiment, novel trial designs can help answer questions of efficacy and safety, which are otherwise challenging to answer using a classic design. N-of-1 designs have been established to offer a Btrial of therapy^to individual patients, and can be a powerful tool in the assessment of comparative effectiveness [79]. These designs are mostly useful in chronic conditions and can improve the certainty of a treatment decision at a single-patient level, with patients serving as their own controls.…”

Optimizing behavioral health interventions with single-case designs: from development to dissemination

“…Although effect size estimates may allow for rank ordering of most to least effective treatments [55], most estimates do not provide metrics that are comparable to effect sizes derived from group designs [31]. However, one estimate that provides metrics comparable to group designs has been developed and tested by Shadish and colleagues [56,57].…”